Casirivimab and imdevimab as investigational monoclonal antibodies for COVID-19 patients – review of the literature
Casirivimab and imdevimab (REGN-COV-2) are investigational monoclonal antibodies approved in November 2020 by the Food and Drug Administration for emergency use in mild and moderate COVID-19. These two noncompeting human IgG1 monoclonal antibodies can target the receptor-binding domain of the spike...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2021-09-01
|
| Series: | Current Issues in Pharmacy and Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/cipms-2021-0030 |